Recommendations on prevention of infections in patients with T-cell lymphomas: a narrative review and synthesis

References

• Cazzola M. Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. Washington (DC): American Society of Hematology; 2016. p. 2361–2364. doi:10.1182/blood-2016-03-657379
   Google Scholar
• Kempf W, Mitteldorf C. Cutaneous T-cell lymphomas—an update 2021. Hematol Oncol. 2021;39 Suppl 1(S1):46–51. doi:10.1002/hon.2850
   PubMedGoogle Scholar
• Wang H, Fu B-B, Gale RP, et al. NK-/T-cell lymphomas. Leukemia. 2021;35(9):2460–2468. doi:10.1038/s41375-021-01313-2
   PubMed Web of Science ®Google Scholar
• Fiore D, Cappelli LV, Broccoli A, et al. Peripheral T cell lymphomas: from the bench to the clinic. Nat Rev Cancer. 2020;20(6):323–342. doi:10.1038/s41568-020-0247-0
   PubMed Web of Science ®Google Scholar
• Sethi T, Montanari F, Foss F. Safety considerations with the current treatments for peripheral T-cell lymphoma. Expert Opin Drug Saf. 2022;21(5):653–660. doi:10.1080/14740338.2022.2036120
   PubMed Web of Science ®Google Scholar
• Wudhikarn K, Bennani NN. How to sequence therapies in peripheral T cell lymphoma. Curr Treat Options Oncol. 2021;22(9):74. doi:10.1007/s11864-021-00873-w
   PubMed Web of Science ®Google Scholar
• Watanabe K, Gomez AM, Kuramitsu S, et al. Identifying highly active anti-CCR4-CAR T cells for the treatment of T-cell lymphoma. Blood Adv. 2023;7(14):3416–3430. doi:10.1182/bloodadvances.2022008327
   PubMed Web of Science ®Google Scholar
• Rowan AG, Ponnusamy K, Ren H, et al. CAR-iNKT cells targeting clonal TCRVβ chains as a precise strategy to treat T cell lymphoma. Front Immunol. 2023;14:1118681. doi:10.3389/fimmu.2023.1118681
   PubMed Web of Science ®Google Scholar
• Taplitz RA, Kennedy EB, Flowers CR. Antimicrobial prophylaxis for adult patients with Cancer-Related immunosuppression: ASCO and IDSA clinical practice guideline update summary. J Oncol Pract. 2018;14(11):692–695. doi:10.1200/JOP.18.00366
   PubMed Web of Science ®Google Scholar
• Bachy E, Camus V, Thieblemont C, et al. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-Cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA). J Clin Oncol. 2022;40(3):242–251. doi:10.1200/JCO.21.01815
   PubMed Web of Science ®Google Scholar
• Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229–240. doi:10.1016/S0140-6736(18)32984-2
   PubMed Web of Science ®Google Scholar
• Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the german High-Grade Non-Hodgkin lymphoma study group. Blood. 2010;116(18):3418–3425. doi:10.1182/blood-2010-02-270785
   PubMed Web of Science ®Google Scholar
• Advani RH, Skrypets T, Civallero M, et al. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell project. Blood. 2021;138(3):213–220. doi:10.1182/blood.2020010387
   PubMed Web of Science ®Google Scholar
• Dumas G, Biard L, Givel C, et al. Intensive care unit admission in patients with T cell lymphomas: clinical features and outcome. Ann Hematol. 2019;98(1):195–203. doi:10.1007/s00277-018-3496-1
   PubMed Web of Science ®Google Scholar
• d‘Amore F, Leppä S, Silva M, et al. Final analysis of the Front-Line phase III randomized ACT-1 trial in younger patients with systemic peripheral T-Cell lymphoma treated with CHOP chemotherapy with or without alemtuzumab and consolidated by autologous hematopoietic stem cell transplant. Blood. 2018;132(Supplement 1):998–998. doi:10.1182/blood-2018-99-110429
   Google Scholar
• Wulf GG, Altmann B, Ziepert M, et al. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. Leukemia. 2021;35(1):143–155. doi:10.1038/s41375-020-0838-5
   PubMed Web of Science ®Google Scholar
• Altmann B, Wulf G, Truemper L, et al. Alemtuzumab added to CHOP for treatment of peripheral T-Cell lymphoma (PTCL) in previously untreated young and elderly patients: pooled analysis of the international ACT-1/2 phase III trials. Blood. 2018;132(Supplement 1):1622–1622. doi:10.1182/blood-2018-99-112076
   Google Scholar
• Ko T, Seah C, Gilbertson M, et al. A description of the type, frequency and severity of infections among sixteen patients treated for T-Cell lymphoma. J Hematol. 2021;10(3):123–129. doi:10.14740/jh838
   PubMedGoogle Scholar
• Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, Open-Label, phase II study of romidepsin in relapsed or refractory peripheral T-Cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631–636. doi:10.1200/JCO.2011.37.4223
   PubMed Web of Science ®Google Scholar
• Foss F, Coiffier B, Horwitz S, et al. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomark Res. 2014;2(1):16. doi:10.1186/2050-7771-2-16
   PubMedGoogle Scholar
• Dupuis J, Morschhauser F, Ghesquières H, et al. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study. Lancet Haematol. 2015;2(4):e160-5–e165. doi:10.1016/S2352-3026(15)00023-X
   PubMed Web of Science ®Google Scholar
• Maruyama D, Tobinai K, Ogura M, et al. Romidepsin in japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study. Int J Hematol. 2017;106(5):655–665. doi:10.1007/s12185-017-2286-1
   PubMed Web of Science ®Google Scholar
• Chiappella A, Dodero A, Evangelista A, et al. Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated peripheral T-Cell lymphoma: results of the PTCL13 phase Ib/II study. Leukemia. 2023;37(2):433–440. doi:10.1038/s41375-022-01780-1
   PubMedGoogle Scholar
• O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182–1189. doi:10.1200/JCO.2010.29.9024
   PubMed Web of Science ®Google Scholar
• Shimony S, Horowitz N, Ribakovsky E, et al. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: real-life data from a national multicenter observational study. Hematol Oncol. 2019;37(5):569–577. doi:10.1002/hon.2691
   PubMed Web of Science ®Google Scholar
• Kalac M, Tam CS, Goldfinger M, et al. A real world experience of combined treatment with romidepsin and azacitidine in patients with peripheral T-Cell lymphoma. Blood. 2021;138(Supplement 1):4550–4550. doi:10.1182/blood-2021-144651
   Google Scholar
• Vu K, Wu C-H, Yang C-Y, et al. Romidepsin plus liposomal doxorubicin is safe and effective in patients with relapsed or refractory T-Cell lymphoma: results of a phase I Dose-Escalation study. Clin Cancer Res. 2020;26(5):1000–1008. doi:10.1158/1078-0432.CCR-19-2152
   PubMed Web of Science ®Google Scholar
• Bhurani M, Admojo L, Van Der Weyden C, et al. Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study. Leuk Lymphoma. 2021;62(2):330–336. doi:10.1080/10428194.2020.1827241
   PubMed Web of Science ®Google Scholar
• Hong X, Song Y, Huang H, et al. Pralatrexate in chinese patients with relapsed or refractory peripheral T-cell lymphoma: a single-arm, multicenter study. Target Oncol. 2019;14(2):149–158. doi:10.1007/s11523-019-00630-y
   PubMed Web of Science ®Google Scholar
• Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (gruppo italiano terapie innovative nei linfomi) prospective multicenter trial. Blood. 2007;110(7):2316–2323. doi:10.1182/blood-2007-02-074641
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095–3100. doi:10.1182/blood-2013-12-542142
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709–2717. doi:10.1182/blood-2017-05-780049
   PubMed Web of Science ®Google Scholar
• Stefania Infante M, Fernández-Cruz A, Núñez L, et al. Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: a multicentric real-world study. Cancer Med. 2021;10(21):7629–7640. doi:10.1002/cam4.4293
   PubMed Web of Science ®Google Scholar
• Van de Wyngaert Z, Coppo P, Cervera P, et al. Combination of brentuximab-vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T-cell lymphoma. Eur J Haematol. 2021;106(4):467–472. doi:10.1111/ejh.13568
   PubMed Web of Science ®Google Scholar
• Binder C, Ziepert M, Pfreundschuh M, et al. CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial. Ann Hematol. 2013;92(11):1521–1528. doi:10.1007/s00277-013-1880-4
   PubMed Web of Science ®Google Scholar
• Horwitz S, O'Connor OA, Pro B, et al. The ECHELON-2 trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma⋆. Ann Oncol. 2022;33(3):288–298. doi:10.1016/j.annonc.2021.12.002
   PubMed Web of Science ®Google Scholar
• Ruan J, Moskowitz A, Mehta-Shah N, et al. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma (PTCL). Blood. 2023;141(18):2194–2205. doi:10.1182/blood.2022018254
   PubMed Web of Science ®Google Scholar
• Martin SI, Marty FM, Fiumara K, et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis. 2006;43(1):16–24. doi:10.1086/504811
   PubMed Web of Science ®Google Scholar
• Vallejo C, Ríos E, de la Serna J, et al. Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab. Expert Rev Hematol. 2011;4(1):9–16. doi:10.1586/ehm.10.77
   PubMed Web of Science ®Google Scholar
• Thursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol. 2006;132(1):3–12. doi:10.1111/j.1365-2141.2005.05789.x
   PubMed Web of Science ®Google Scholar
• Tay KH, Slavin MA, Thursky KA, et al. Cytomegalovirus DNAemia and disease: current-era epidemiology, clinical characteristics and outcomes in cancer patients other than allogeneic hematopoietic transplantation. Intern Med J. 2022;52(10):1759–1767. doi:10.1111/imj.15496
   PubMed Web of Science ®Google Scholar
• O'Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma. 2006;7(2):125–130. doi:10.3816/CLM.2006.n.049
   PubMedGoogle Scholar
• Kluin-Nelemans H, van Marwijk Kooy M, Lugtenburg P, et al. Intensified alemtuzumab–CHOP therapy for peripheral T-cell lymphoma. Ann Oncol. 2011;22(7):1595–1600. doi:10.1093/annonc/mdq635
   PubMed Web of Science ®Google Scholar
• Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103(8):2920–2924. doi:10.1182/blood-2003-10-3389
   PubMed Web of Science ®Google Scholar
• Saito Y, Takenaka H, Chin T, et al. Cytomegalovirus in cutaneous ulcers in a patient with adult T-cell lymphoma. Acta Derm Venereol. 2006;86(2):181–182. doi:10.2340/00015555-0031
   PubMed Web of Science ®Google Scholar
• Tudesq JJ, Vincent L, Lebrun J, et al. Cytomegalovirus infection with retinitis after brentuximab vedotin treatment for CD30(+) lymphoma. Open Forum Infect Dis. 2017;4(2):ofx091.
   PubMed Web of Science ®Google Scholar
• Carson KR, Newsome SD, Kim EJ, et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern network on adverse reactions (SONAR) project. Cancer. 2014;120(16):2464–2471. doi:10.1002/cncr.28712
   PubMed Web of Science ®Google Scholar
• Bekiaris V, Gaspal F, Kim MY, et al. Synergistic OX40 and CD30 signals sustain CD8+ T cells during antigenic challenge. Eur J Immunol. 2009;39(8):2120–2125. doi:10.1002/eji.200939424
   PubMed Web of Science ®Google Scholar
• Clarivet B, Vincent L, Vergely L, et al. Adverse reactions related to brentuximab vedotin use: a real-life retrospective study. Therapie. 2019;74(3):343–346. doi:10.1016/j.therap.2018.07.004
   PubMed Web of Science ®Google Scholar
• Richardson NC, Kasamon YL, Chen H, et al. FDA approval summary: brentuximab vedotin in First-Line treatment of peripheral T-Cell lymphoma. Oncologist. 2019;24(5):e180–e7. doi:10.1634/theoncologist.2019-0098
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Coenen JL, Boers JE, et al. EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Blood. 2008;112(4):1039–1041. doi:10.1182/blood-2008-02-138800
   PubMed Web of Science ®Google Scholar
• Weisel KC, Weidmann E, Anagnostopoulos I, et al. Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma. Int J Hematol. 2008;88(4):434–440. doi:10.1007/s12185-008-0176-2
   PubMed Web of Science ®Google Scholar
• Hagan JB, Ender E, Divekar RD, et al. Risk for postmarket black box warnings in FDA-Approved monoclonal antibodies. Mayo Clin Proc Innov Qual Outcomes. 2022;6(1):69–76. doi:10.1016/j.mayocpiqo.2021.11.009
   PubMedGoogle Scholar
• Maschmeyer G, De Greef J, Mellinghoff SC, et al. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. Posit Paper Eur Conf Infect Leuk. 2019;33(4):844–862. doi:10.1038/s41375-019-0388-x
   Google Scholar
• Raisch DW, Rafi JA, Chen C, et al. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system. Expert Opin Drug Saf. 2016;15(8):1003–1011. doi:10.1080/14740338.2016.1198775
   PubMed Web of Science ®Google Scholar
• Sawayama Y, Kato T, Watanabe H[, et al. Progressive multifocal leukoencephalopathy during the treatment for mycosis fungoides]. Rinsho Ketsueki. 2022;63(3):206–210.
   PubMedGoogle Scholar
• Bennett CL, Focosi D, Socal MP, et al. Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern network on adverse reactions. Lancet Haematol. 2021;8(8):e593–e604. doi:10.1016/S2352-3026(21)00167-8
   PubMed Web of Science ®Google Scholar
• Buckstein R, Fraser G, Cheung M, et al. Alemtuzumab and CHOP chemotherapy for the treatment of aggressive histology peripheral T cell lymphomas: a Multi-Center phase I study. Clin Lymphoma Myeloma Leuk. 2016;16(1):18–28.e4. doi:10.1016/j.clml.2015.11.008
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8):1068–1075.
   PubMed Web of Science ®Google Scholar
• Beltran BE, Aguilar C, Quiñones P, et al. The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma. 2016;57(1):58–62. doi:10.3109/10428194.2015.1045897
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Morales D, Quinones P, et al. Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma. 2010;51(10):1822–1828. doi:10.3109/10428194.2010.508189
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang S, Mi R, et al. Prognostic significance of the neutrophil-to-lymphocyte ratio in peripheral T-cell lymphoma: a meta-analysis. Cancer Cell Int. 2021;21(1):688. doi:10.1186/s12935-021-02391-z
   PubMed Web of Science ®Google Scholar
• Li Q, Gao S, Ma J, et al. A lower ALC/AMC ratio is associated with poor prognosis of peripheral T-cell lymphoma-not otherwise specified. Leuk Res. 2018;73:5–11. doi:10.1016/j.leukres.2018.07.020
   PubMed Web of Science ®Google Scholar
• Dummer R, Vermeer MH, Scarisbrick JJ, et al. Cutaneous T cell lymphoma. Nat Rev Dis Primers. 2021;7(1):61. doi:10.1038/s41572-021-00296-9
   PubMed Web of Science ®Google Scholar
• Axelrod PI, Lorber B, Vonderheid EC. Infections complicating mycosis fungoides and sezary syndrome. Jama. 1992;267(10):1354–1358. doi:10.1001/jama.1992.03480100060031
   PubMed Web of Science ®Google Scholar
• Allen PB, Switchenko J, Ayers A, et al. Risk of bacteremia in patients with cutaneous T-cell lymphoma (CTCL). Leuk Lymphoma. 2020;61(11):2652–2658. doi:10.1080/10428194.2020.1779259
   PubMed Web of Science ®Google Scholar
• Allen PB, Goyal S, Switchenko J, et al. Mitigation strategies among cutaneous T-cell lymphoma patients with positive Staphylococcus aureus skin and soft tissue cultures have unclear impacts on the risk of subsequent bacteremia. Leuk Lymphoma. 2023;64(3):597–604. doi:10.1080/10428194.2022.2081324
   PubMed Web of Science ®Google Scholar
• Blaizot R, Ouattara E, Fauconneau A, et al. Infectious events and associated risk factors in mycosis fungoides/sézary syndrome: a retrospective cohort study. Br J Dermatol. 2018;179(6):1322–1328. doi:10.1111/bjd.17073
   PubMed Web of Science ®Google Scholar
• Edigin E, Eseaton PO. 26789 Analysis of cutaneous T cell lymphoma hospitalizations in the United States. J Am Acad Dermatol. 2021;85(3):AB25. doi:10.1016/j.jaad.2021.06.125
   Web of Science ®Google Scholar
• Dummer R, Quaglino P, Becker JC, et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol. 2012;30(33):4091–4097. doi:10.1200/JCO.2011.39.8065
   PubMed Web of Science ®Google Scholar
• Marchi E, Alinari L, Tani M, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer. 2005;104(11):2437–2441. doi:10.1002/cncr.21449
   PubMed Web of Science ®Google Scholar
• Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23(17):3923–3931. doi:10.1200/JCO.2005.14.167
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, Cohen MH, et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12(10):1247–1252. doi:10.1634/theoncologist.12-10-1247
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31–39. doi:10.1182/blood-2006-06-025999
   PubMed Web of Science ®Google Scholar
• Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192–1204. doi:10.1016/S1470-2045(18)30379-6
   PubMed Web of Science ®Google Scholar
• Duvic M, Tetzlaff MT, Gangar P, et al. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33(32):3759–3765. doi:10.1200/JCO.2014.60.3787
   PubMed Web of Science ®Google Scholar
• Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and sézary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33(32):3750–3758. doi:10.1200/JCO.2014.60.3969
   PubMed Web of Science ®Google Scholar
• Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–566. doi:10.1016/S0140-6736(17)31266-7
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Demierre M-F, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-Cell lymphoma. J Clin Oncol. 2010;28(29):4485–4491. doi:10.1200/JCO.2010.28.9066
   PubMed Web of Science ®Google Scholar
• Duvic M, Bates SE, Piekarz R, et al. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. Leuk Lymphoma. 2018;59(4):880–887. doi:10.1080/10428194.2017.1361022
   PubMed Web of Science ®Google Scholar
• Saed G, Fivenson DP, Naidu Y, et al. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas sezary syndrome expresses a Th2-type profile. J Invest Dermatol. 1994;103(1):29–33. doi:10.1111/1523-1747.ep12388985
   PubMed Web of Science ®Google Scholar
• Vermeer MH, van Doorn R, Dukers D, et al. CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, fas ligand, and killing inhibitory receptors and their relationship with clinical behavior. J Clin Oncol. 2001;19(23):4322–4329. doi:10.1200/JCO.2001.19.23.4322
   PubMed Web of Science ®Google Scholar
• van der Wekken L, Herbrink J, Snijders D, et al. Disseminated Mycobacterium chelonae infection in a patient with T-cell lymphoma. Hematol Oncol Stem Cell Ther. 2017;10(2):89–92. doi:10.1016/j.hemonc.2016.04.004
   PubMedGoogle Scholar
• Lindahl LM, Iversen L, Ødum N, et al. Staphylococcus aureus and antibiotics in cutaneous T-Cell lymphoma. Dermatology. 2022;238(3):551–553. doi:10.1159/000517829
   PubMed Web of Science ®Google Scholar
• Willerslev-Olsen A, Krejsgaard T, Lindahl LM, et al. Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. Blood. J Am Soc Hematol. 2016;127(10):1287–1296. doi:10.1182/blood-2015-08-662353
   Google Scholar
• Tokura Y, Heald PW, Yan SL, et al. Stimulation of cutaneous T-cell lymphoma cells with superantigenic staphylococcal toxins. J Invest Dermatol. 1992;98(1):33–37. doi:10.1111/1523-1747.ep12494184
   PubMed Web of Science ®Google Scholar
• Blümel E, Munir Ahmad S, Nastasi C, et al. Staphylococcus aureus alpha-toxin inhibits CD8+ T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma. Oncoimmunology. 2020;9(1):1751561. doi:10.1080/2162402X.2020.1751561
   PubMed Web of Science ®Google Scholar
• Ogata M, Satou T, Kawano R, et al. High incidence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus reactivation in patients receiving cytotoxic chemotherapy for adult T cell leukemia. J Med Virol. 2011;83(4):702–709. doi:10.1002/jmv.22013
   PubMed Web of Science ®Google Scholar
• Kim JK, Ahmad A, Selim MA, et al. Disseminated cutaneous cytomegalovirus infection following total body electron beam irradiation for mycosis fungoides. JAMA Dermatol. 2015;151(12):1380–1381. doi:10.1001/jamadermatol.2015.2233
   PubMed Web of Science ®Google Scholar
• Sami R, Aeini S, Sadegh R. Crazy-Paving pattern due to herpetic pneumonia in a patient with mycosis fungoides: a case report. Tanaffos. 2017;16(4):309–312.
   PubMedGoogle Scholar
• Goldgeier MH, Cohen SR, Braverman IM, et al. An unusual and fatal case of disseminated cutaneous herpes simplex. Infection in a patient with cutaneous T cell lymphoma (mycosis fungoides). J Am Acad Dermatol. 1981;4(2):176–180. doi:10.1016/s0190-9622(81)70021-5
   PubMed Web of Science ®Google Scholar
• Kabashima K, Honda T, Ginhoux F, et al. The immunological anatomy of the skin. Nat Rev Immunol. 2019;19(1):19–30. doi:10.1038/s41577-018-0084-5
   PubMed Web of Science ®Google Scholar
• Torrealba MP, Manfrere KC, Miyashiro DR, et al. Chronic activation profile of circulating CD8+ T cells in sézary syndrome. Oncotarget. 2018;9(3):3497–3506. doi:10.18632/oncotarget.23334
   PubMedGoogle Scholar
• Abeni D, Frontani M, Sampogna F, et al. Circulating CD8+ lymphocytes, white blood cells, and survival in patients with mycosis fungoides. Br J Dermatol. 2005;153(2):324–330. doi:10.1111/j.1365-2133.2005.06755.x
   PubMed Web of Science ®Google Scholar
• Boonk SE, Zoutman WH, Marie-Cardine A, et al. Evaluation of immunophenotypic and molecular biomarkers for sezary syndrome using standard operating procedures: a multicenter study of 59 patients. J Invest Dermatol. 2016;136(7):1364–1372. doi:10.1016/j.jid.2016.01.038
   PubMed Web of Science ®Google Scholar
• Watson S, Marx JB. Mogamulizumab-kpkc: a novel therapy for the treatment of cutaneous T-Cell lymphoma. J Adv Pract Oncol. 2019;10(8):883–888.
   PubMedGoogle Scholar
• Nosaka K, Crawford B, Yi J, et al. Systematic review of survival outcomes for relapsed or refractory adult T-cell leukemia-lymphoma. Eur J Haematol. 2022;108(3):212–222. doi:10.1111/ejh.13728
   PubMed Web of Science ®Google Scholar
• Wang S, Jayarangaiah A, Malone M, et al. Risk of hepatitis B reactivation and cytomegalovirus related infections with mogamulizumab: a retrospective study of international pharmacovigilance database. EClinicalMedicine. 2020;28:100601. doi:10.1016/j.eclinm.2020.100601
   PubMedGoogle Scholar
• Tsambiras PE, Patel S, Greene JN, et al. Infectious complications of cutaneous T-Cell lymphoma. Cancer Control. 2001;8(2):185–188. doi:10.1177/107327480100800213
   PubMedGoogle Scholar
• Grier DD, Lewis Z, Palavecino EL. Bone marrow involvement by Pneumocystis jiroveci. Br J Haematol. 2009;145(2):149–149. doi:10.1111/j.1365-2141.2008.07438.x
   PubMedGoogle Scholar
• Gibbs SDJ, Herbert KE, McCormack C, et al. Alemtuzumab: effective monotherapy for simultaneous B-cell chronic lymphocytic leukaemia and sézary syndrome. Eur J Haematol. 2004;73(6):447–449. doi:10.1111/j.1600-0609.2004.00332.x
   PubMed Web of Science ®Google Scholar
• Adithya Sateesh B, Bhagat YV, Thomas SE, et al. Recurrent bacterial infections in cutaneous T-cell lymphoma. Cureus. 2022;14(1):e20912. doi:10.7759/cureus.20912
   PubMed Web of Science ®Google Scholar
• Harkins CP, MacGibeny MA, Thompson K, et al. Cutaneous T-Cell lymphoma skin microbiome is characterized by shifts in certain commensal bacteria but not viruses when compared with healthy controls. J Invest Dermatol. 2021;141(6):1604–1608. doi:10.1016/j.jid.2020.10.021
   PubMed Web of Science ®Google Scholar
• Posner LE, Fossieck BE, Jr., Eddy JL, et al. Septicemic complications of the cutaneous T-cell lymphomas. Am J Med. 1981;71(2):210–216. doi:10.1016/0002-9343(81)90107-8
   PubMed Web of Science ®Google Scholar
• Uchiyama T. Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu Rev Immunol. 1997;15(1):15–37. doi:10.1146/annurev.immunol.15.1.15
   PubMedGoogle Scholar
• Shimoyama M. Group LS. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the lymphoma study group (1984–87). Br J Haematol. 1991;79(3):428–437. doi:10.1111/j.1365-2141.1991.tb08051.x
   PubMed Web of Science ®Google Scholar
• Katsuya H, Ishitsuka K, Utsunomiya A, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126(24):2570–2577. doi:10.1182/blood-2015-03-632489
   PubMed Web of Science ®Google Scholar
• Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan clinical oncology group study JCOG9801. J Clin Oncol. 2007;25(34):5458–5464. doi:10.1200/JCO.2007.11.9958
   PubMed Web of Science ®Google Scholar
• Toyoda K, Tsukasaki K, Machida R, et al. Possibility of a risk-adapted treatment strategy for untreated aggressive adult T-cell leukaemia-lymphoma (ATL) based on the ATL prognostic index: a supplementary analysis of the JCOG9801. Br J Haematol. 2019;186(3):440–447. doi:10.1111/bjh.15950
   PubMed Web of Science ®Google Scholar
• Itonaga H, Taguchi J, Fukushima T, et al. Distinct clinical features of infectious complications in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis in the Nagasaki transplant group. Biol Blood Marrow Transplant. 2013;19(4):607–615. doi:10.1016/j.bbmt.2013.01.011
   PubMed Web of Science ®Google Scholar
• Suzumiya J, Marutsuka K, Nabeshima K, et al. Autopsy findings in 47 cases of adult T-cell leukemia/lymphoma in Miyazaki prefecture, Japan. Leuk Lymphoma. 1993;11(3-4):281–286. doi:10.3109/10428199309087005
   PubMed Web of Science ®Google Scholar
• Pawson R, Richardson DS, Pagliuca A, et al. Adult T-Cell leukemia/lymphoma in london: clinical experience of 21 cases. Leuk Lymphoma. 1998;31(1-2):177–185. doi:10.3109/10428199809057597
   PubMed Web of Science ®Google Scholar
• Yang L, Liu H, Xu XH, et al. Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type. Med Oncol. 2013;30(4):720. doi:10.1007/s12032-013-0720-7
   PubMed Web of Science ®Google Scholar
• Kim SM, Park S, Oh DR, et al. Extra-nodal natural killer/T cell lymphoma in elderly patients: the impact of aging on clinical outcomes and treatment tolerability. Ann Hematol. 2016;95(4):581–591. doi:10.1007/s00277-015-2581-y
   PubMed Web of Science ®Google Scholar
• Kwong Y, Kim S, Tse E, et al. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma. Ann Oncol. 2018;29(1):256–263. doi:10.1093/annonc/mdx684
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell tumor study group study. J Clin Oncol. 2011;29(33):4410–4416. doi:10.1200/JCO.2011.35.6287
   PubMed Web of Science ®Google Scholar
• Pokrovsky VS, Vinnikov D. Defining the toxicity of current regimens for extranodal NK/T cell lymphoma: a systematic review and metaproportion. Expert Rev Anticancer Ther. 2019;19(1):93–104. doi:10.1080/14737140.2019.1549992
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci. 2008;99(5):1016–1020. doi:10.1111/j.1349-7006.2008.00768.x
   PubMed Web of Science ®Google Scholar
• Zhou Z, Li X, Chen C, et al. Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients. Ann Hematol. 2014;93(11):1889–1894. doi:10.1007/s00277-014-2136-7
   PubMed Web of Science ®Google Scholar
• Wang L. Should DDGP regimen be the standard of care for advanced extranodal NK/T-Cell lymphoma? The new staging system matters. JAMA Oncol. 2023;9(2):278–279. doi:10.1001/jamaoncol.2022.6460
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang L, Liu X, et al. Efficacy and safety of a Pegasparaginase-Based chemotherapy regimen vs an L-asparaginase–based chemotherapy regimen for newly diagnosed advanced extranodal natural killer/T-Cell lymphoma: a randomized clinical trial. JAMA Oncol. 2022;8(7):1035–1041. doi:10.1001/jamaoncol.2022.1968
   PubMed Web of Science ®Google Scholar
• Li X, Cui Y, Sun Z, et al. DDGP versus SMILE in newly diagnosed advanced natural killer/T-Cell lymphoma: a randomized controlled, multicenter, open-label study in China. Clin Cancer Res. 2016;22(21):5223–5228. doi:10.1158/1078-0432.CCR-16-0153
   PubMed Web of Science ®Google Scholar
• Lurain K, Uldrick TS. De-escalating chemotherapy for advanced extranodal natural killer/T-Cell lymphoma: a step toward improved treatment of a rare Virus-Associated cancer. JAMA Oncol. 2022;8(7):977–979. doi:10.1001/jamaoncol.2022.1713
   PubMed Web of Science ®Google Scholar
• Wu W, Ren K, Chen X, et al. Comparison of the clinical efficacies of two L-asparaginase-based chemotherapy regimens for newly diagnosed nasal-type extranodal NK/T-cell lymphoma. Cancer Med. 2023;12(8):9458–9470. doi:10.1002/cam4.5708
   PubMed Web of Science ®Google Scholar
• Chaubard S, Marouf A, Lavergne D, et al. Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L-asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T-cell lymphoma: a french retrospective study. Br J Haematol. 2023;201(4):673–681. doi:10.1111/bjh.18689
   PubMed Web of Science ®Google Scholar
• Zhong H, Cheng S, Zhang X, et al. Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: a randomized phase III study. Innovation (Camb). 2023;4(3):100426. doi:10.1016/j.xinn.2023.100426
   PubMedGoogle Scholar
• Ji J, Liu T, Xiang B, et al. A study of gemcitabine, l-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type. Leuk Lymphoma. 2014;55(12):2955–2957. doi:10.3109/10428194.2014.907894
   PubMed Web of Science ®Google Scholar
• Tse E, Zhao W-L, Xiong J, et al. How we treat NK/T-cell lymphomas. J Hematol Oncol. 2022;15(1):74. doi:10.1186/s13045-022-01293-5
   PubMed Web of Science ®Google Scholar
• Cai J, Liu P, Huang H, et al. Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma. Signal Transduct Target Ther. 2020;5(1):289. doi:10.1038/s41392-020-00331-3
   PubMed Web of Science ®Google Scholar
• Cooley L, Dendle C, Wolf J, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J. 2014;44(12b):1350–1363. doi:10.1111/imj.12599
   PubMed Web of Science ®Google Scholar
• Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71(9):2397–2404. doi:10.1093/jac/dkw157
   PubMed Web of Science ®Google Scholar
• Reynolds G, Haeusler G, Slavin MA, et al. Latent infection screening and prevalence in cancer patients born outside of Australia: a universal versus risk-based approach? Support Care Cancer. 2021;29(11):6193–6200. doi:10.1007/s00520-021-06116-w
   PubMed Web of Science ®Google Scholar
• Teh BW. Vaccination schedules. In: Cornely OA, Hoenigl M, editors. Infection management in hematology. Cham: Springer International Publishing; 2021. p. 77–105.
   Google Scholar
• Lim SH, Stuart B, Joseph-Pietras D, et al. Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. Nat Cancer. 2022;3(5):552–564. doi:10.1038/s43018-022-00364-3
   PubMedGoogle Scholar
• Rieger C, Liss B, Mellinghoff S, et al. Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors—guideline of the infectious diseases working party (AGIHO) of the german society for hematology and medical oncology (DGHO). Ann Oncol. 2018;29(6):1354–1365. doi:10.1093/annonc/mdy117
   PubMed Web of Science ®Google Scholar
• Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44–e100. doi:10.1093/cid/cit684
   PubMed Web of Science ®Google Scholar
• ATAGoI (ATAGI). The Australian immunisation handbook. In: Health AGDo, editor. Canberra: Australian Government Department of Health; 2017.
   Google Scholar